These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. Management and Outcomes for Neovascular Age-Related Macular Degeneration: Analysis of United States Electronic Health Records. Kiss S; Campbell J; Almony A; Shih V; Serbin M; LaPrise A; Wykoff CC Ophthalmology; 2020 Sep; 127(9):1179-1188. PubMed ID: 32345477 [TBL] [Abstract][Full Text] [Related]
9. Switching from aflibercept to brolucizumab for the treatment of refractory neovascular age-related macular degeneration. Ota H; Takeuchi J; Nakano Y; Horiguchi E; Taki Y; Ito Y; Terasaki H; Nishiguchi KM; Kataoka K Jpn J Ophthalmol; 2022 May; 66(3):278-284. PubMed ID: 35233693 [TBL] [Abstract][Full Text] [Related]
10. Short-term outcomes of switching to brolucizumab in japanese patients with neovascular age-related macular degeneration. Kitajima Y; Maruyama-Inoue M; Ikeda S; Ito A; Inoue T; Yanagi Y; Kadonosono K Jpn J Ophthalmol; 2022 Nov; 66(6):511-517. PubMed ID: 36149566 [TBL] [Abstract][Full Text] [Related]
11. Brolucizumab Versus Aflibercept in Participants with Neovascular Age-Related Macular Degeneration: A Randomized Trial. Dugel PU; Jaffe GJ; Sallstig P; Warburton J; Weichselberger A; Wieland M; Singerman L Ophthalmology; 2017 Sep; 124(9):1296-1304. PubMed ID: 28551167 [TBL] [Abstract][Full Text] [Related]
12. Twelve-Month Outcomes of Ranibizumab vs. Aflibercept for Neovascular Age-Related Macular Degeneration: Data from an Observational Study. Gillies MC; Nguyen V; Daien V; Arnold JJ; Morlet N; Barthelmes D Ophthalmology; 2016 Dec; 123(12):2545-2553. PubMed ID: 27707549 [TBL] [Abstract][Full Text] [Related]
13. MERLIN: Phase 3a, Multicenter, Randomized, Double-Masked Trial of Brolucizumab in Participants with Neovascular Age-Related Macular Degeneration and Persistent Retinal Fluid. Khanani AM; Brown DM; Jaffe GJ; Wykoff CC; Adiguzel E; Wong R; Meng X; Heier JS; Ophthalmology; 2022 Sep; 129(9):974-985. PubMed ID: 35537533 [TBL] [Abstract][Full Text] [Related]
14. Early Experience With Brolucizumab Treatment of Neovascular Age-Related Macular Degeneration. Enríquez AB; Baumal CR; Crane AM; Witkin AJ; Lally DR; Liang MC; Enríquez JR; Eichenbaum DA JAMA Ophthalmol; 2021 Apr; 139(4):441-448. PubMed ID: 33630045 [TBL] [Abstract][Full Text] [Related]
15. Safety Outcomes of Brolucizumab in Neovascular Age-Related Macular Degeneration: Results From the IRIS Registry and Komodo Healthcare Map. Khanani AM; Zarbin MA; Barakat MR; Albini TA; Kaiser PK; B G; Agashivala N; Yu JS; Wykoff CC; MacCumber MW JAMA Ophthalmol; 2022 Jan; 140(1):20-28. PubMed ID: 34817566 [TBL] [Abstract][Full Text] [Related]
16. Risk of Inflammation, Retinal Vasculitis, and Retinal Occlusion-Related Events with Brolucizumab: Post Hoc Review of HAWK and HARRIER. Monés J; Srivastava SK; Jaffe GJ; Tadayoni R; Albini TA; Kaiser PK; Holz FG; Korobelnik JF; Kim IK; Pruente C; Murray TG; Heier JS Ophthalmology; 2021 Jul; 128(7):1050-1059. PubMed ID: 33207259 [TBL] [Abstract][Full Text] [Related]
17. Two-year outcomes of treat-and-extend regimen with intravitreal brolucizumab for treatment-naïve neovascular age-related macular degeneration with type 1 macular neovascularization. Matsumoto H; Hoshino J; Nakamura K; Akiyama H Sci Rep; 2023 Feb; 13(1):3249. PubMed ID: 36828853 [TBL] [Abstract][Full Text] [Related]
18. Effects of switching from ranibizumab to aflibercept in eyes with exudative age-related macular degeneration. Barthelmes D; Campain A; Nguyen P; Arnold JJ; McAllister IL; Simpson JM; Hunyor AP; Guymer R; Essex RW; Morlet N; Gillies MC; Br J Ophthalmol; 2016 Dec; 100(12):1640-1645. PubMed ID: 26994110 [TBL] [Abstract][Full Text] [Related]
19. Short-term real-world outcomes following intravitreal brolucizumab for neovascular AMD: SHIFT study. Bulirsch LM; Saßmannshausen M; Nadal J; Liegl R; Thiele S; Holz FG Br J Ophthalmol; 2022 Sep; 106(9):1288-1294. PubMed ID: 33846161 [TBL] [Abstract][Full Text] [Related]
20. Changes in the uninjected contralateral eye after intravitreal brolucizumab for exudative age-related macular degeneration. Mora P; Bellucci C; Radice LM; Manzotti F; Gandolfi S Eur J Ophthalmol; 2024 Jan; 34(1):NP104-NP107. PubMed ID: 37424299 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]